VIVACELLE BIO
Vivacelle Bio is a clinical stage biotechnology company focused on creating products that utilize phospholipid nanoparticle technology. The Company's first product, VBI-1, is a circulatory support fluid that is a colloid non-blood volume expander that appears to be two to three times more effective than the standard treatment for hypovolemia and safer in animal studies/experiments. It's second product, VBI-S, is specifically-designed to elevate blood pressure in septic shock patients. This new class of resuscitation fluids is called VIVACELLE.
VIVACELLE BIO
Industry:
Biotechnology Clinical Trials Health Care Life Science
Founded:
2013-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.vivacellebio.com
Total Employee:
1+
Status:
Active
Contact:
(844)848-2235
Email Addresses:
[email protected]
Total Funding:
2.45 M USD
Technology used in webpage:
Euro SPF Wix GoDaddy Email Wix DNS
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Viatris
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Yecuris
Yecuris is a technology development company obsessed with bringing novel tools to aid researchers in their search for cures.
Current Employees Featured
Founder
Official Site Inspections
http://www.vivacellebio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Vivacelle Bio"
Vivacelle Bio | Shock
Jan 29, 2024 · Vivacelle Bio is developing a novel therapeutic for the treatment of septic shock, hemorrhagic shock, and hypovolemia with over 45 patents and candidates in phases III and II.See details»
Vivacelle Bio's President and Chief Innovation Officer to Present …
Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions. Vivacelle's pipeline is led by VBI-S, a Phase 3-ready asset designated for the treatment of …See details»
Contact Us | Vivacelle Bio
Interested in press, investment, partnerships, questions about our science, or any other potential collaborations? Please reach out to us here. We look forward to hearing from you soon!See details»
Vivacelle Bio, Inc. | LinkedIn
VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology.See details»
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat ...
Jul 23, 2024 · Vivacelle's VBI-S is designed to treat hypovolemic patients in urgent need of care due to septic shock. Septic shock impacts approximately two million people in the U.S. each …See details»
Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia …
Sep 3, 2024 · VBI-S is built on the company's pioneering and patented phospholipid nanoparticle technology, which expands intravascular volume and redistributes nitric oxide to elevate blood …See details»
Vivacelle Bio - Crunchbase Company Profile & Funding
Vivacelle Bio is a clinical stage biotechnology company focused on creating products that utilize phospholipid nanoparticle technology. The Company's first product, VBI-1, is a circulatory support fluid that is a colloid non-blood volume …See details»
Vivacelle Bio's President and Chief Innovation Officer to Present …
Jun 1, 2024 · Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions. Vivacelle's pipeline is led by VBI-S, a Phase 3-ready asset designated for the …See details»
Chief Innovation Officer and President - LinkedIn
President, Chief Innovation Officer and Founder of Vivacelle Bio, Inc. a biotechnology company. The first product is Vivacelle a novel phospholipid nanomicelle soybean oil containing fluid for...See details»
Vivacelle Bio Inc. - Chief Information Officer - LinkedIn
VIVACELLE BIO, Inc. is a clinical stage biotechnology company focused on creating products that utilize nanoparticle technology. The Company's first product, VBI-1, is a colloid non-blood...See details»
Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial ...
Oct 20, 2022 · KANSAS CITY, Mo.-- ( BUSINESS WIRE )--Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today …See details»
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat ...
Jul 24, 2024 · Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield - Vivacelle Bio on the Empowered Patient Podcast with Karen JagodaSee details»
Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and ...
Feb 9, 2023 · VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without …See details»
Vivacelle Bio Receives $5.3 Million Award from the US Navy for a ...
FORT WAYNE, Ind., Nov. 24, 2020 /PRNewswire/ -- Vivacelle Bio, Inc. today announces the Department of Defense awarded $5.3 million (USD) dollars for the clinical trial of VBI-S, an …See details»
Vivacelle Bio Company Profile 2024: Valuation, Funding
Developer of a novel intravenous resuscitation fluid technology designed to reverse the consequences of hypovolemia and shock.See details»
Recommended Stories
Jun 1, 2024 · Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions. Vivacelle's pipeline is led by VBI-S, a Phase 3-ready asset designated for the …See details»
Vivacelle Bio and University of Missouri-Kansas City School of …
KANSAS CITY, Mo., Feb. 29, 2024 /PRNewswire/ -- Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed the compelling outcomes of their phase 2a …See details»
Vivacelle Bio Receives $5.3 Million Award from the US Navy for a ...
Nov 24, 2020 · Vivacelle Bio, Inc. is a biopharmaceutical company focused on the discovery of life-saving interventions in critical illnesses due to a broad range of causes such as injuries …See details»
Vivacelle Bio - Craft
Vivacelle Bio is a biotechnology company focused on creating products that utilize nanoparticle technology. Its key product is a colloid non-blood volume expander for the treatment of …See details»